The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors
was coincidentally expanded to a dual inhibition of p38α MAPK and phosphodiesterase 4 …

The tumor necrosis factor-α (TNF-α) cytokine, secreted by activated monocytes/
macrophages and T lymphocytes, is implicated in several diseases, including rheumatoid …

The development of a new series of p38α inhibitors resulted in the identification of two
clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid …

Signal transduction through the p38 mitogen-activated protein (MAP) kinase pathway is
central to the transcriptional and translational control of cytokine and inflammatory mediator …

In search for prodrugs to address the issue of pH-dependent solubility and exposure
associated with 1 (BMS-582949), a previously disclosed phase II clinical p38α MAP kinase …

The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP
kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid …

A novel series of highly potent and selective p38 MAP kinase inhibitors was developed
originating from a substituted N-aryl-6-pyrimidinone scaffold. SAR studies coupled with in …

Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein)
kinase are described which have activity in both cell-based assays of tumor necrosis factor-α …

A novel structural class of p38α MAP kinase inhibitors has been identified via iterative SAR
studies of a focused deck screen hit. Optimization of the lead series generated 6e, BMS …

The p38 mitogen-activated protein kinase (MAPK) is a central signaling molecule in many
proinflammatory pathways, regulating the cellular response to a multitude of external stimuli …